Abstract
Cardiovascular disease is the number one cause of mortality in the Western world, with heart failure representing one of the fastest growing subgroups over the past decade. Heart failure, the progressive loss of cardiac contractile performance resulting in an inability to pump an adequate supply of systemic blood, affects an estimated 5 million Americans with estimated medical costs of $21–$50 billion per year1. A number of common disease disease stimuli can induce heart failure, including hypertension, myocardial infarction, ischemia associated with coronary artery disease, congenital malformation, familial hypertrophic and dilated cardiomyopathies and diabetic cardiomyopathy. Systolic and diastolic dysfunction is common in patients suffering from coronary artery disease and hypertension and is a main cause of heart failure. Hypertrophic growth of cardiomyocytes also occurs in many forms of heart failure and may contribute to the pathogenesis of the failure state2.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Klein L, O’Connor CM, Gattis WA et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003; 91(9 A):18F–40F.
Rothermel BA, Berenji K, Tannous P et al. Differential activation of stress-reponse signaling in load-induced cardiac hypertrophy and failure. Physiol Genomics 2005; 23(1):18–27.
Cummins P, Perry SV. Chemical and immunochemical characteristics of tropomyosins from striated and smooth muscle. Biochem J 1974; 141(1):43–49.
Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 1988; 85(2):339–343.
Wang SM, Greaser ML, Schultz E et al. Studies on cardiac myofibrillogenesis with antibodies to titin, actin, tropomyosin and myosin. J Cell Biol 1988; 107(3):1075–1083.
Muthuchamy M, Pajak L, Howles P. et al. Developmental analysis of tropomyosin gene expression in embryonic stem cells and mouse embryos. Mol Cell Biol 1993; 13(6):3311–3323.
Muthuchamy M, Grupp IL, Grupp G et al. Molecular and physiological effects of overexpressing striated muscle beta-tropomyosin in the adult murine heart. J Biol Chem 1995; 270(51):30593–30603.
Muthuchamy M, Pieples K, Rethinasamy P et al. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res 1999; 85(1):47–56.
Prabhakar R, Boivin GP, Grupp IL et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 2001; 33(10):1815–1828.
Jagatheesan G, Rajan S, Petrashevskaya N et al. Functional importance of the carboxyl-terminal region of striated muscle tropomyosin. J Biol Chem 2003; 278(25):23204–23211.
Jagatheesan G, Rajan S, Petrashevskaya N et al. Physiological significance of troponin T binding domains in striated muscle tropomyosin. Am J Physiol Heart Circ Physiol 2004; 287(4):H1484–1494.
Rajan S, Ahmed RP, Jagatheesan G et al. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circ Res 2007; 101(2):205–214.
Palmiter KA, Kitada Y, Muthuchamy M et al. Exchange of beta-for alpha-tropomyosin in hearts of transgenic mice induces changes in thin filament response to Ca2+, stong cross-brodge binding and protein phosphorylation. J Biol Chem 1996; 271(20):11611–11614.
Wolska BM, Keller RS, Evans CC et al. Correlation between myofilament response to Ca2+ and altered dynamics of contraction and relaxations in transgenic cardiac cells that express beta-tropomyosin. Circ Res 1999; 84(7):745–751.
Pieples K, Wieczorek DF. Tropomyosin 3 increases striated muscle isoform diversity. Biochemistry 2000; 39(28):8291–8297.
Pieples K, Arteaga G, Solaro RJ et al. Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol 2002; 283(4): H1344–1353.
Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62(5):999–1006.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287(10):1308–1320.
Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104(4):557–567.
Watkins H, MacRae C, Thierfelder L et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993; 3(4):333–337.
Thierfelder L, Watkins H, MacRae C et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77(5):701–712.
Tardiff JC. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005; 10(3):237–248.
Nakajima-Taniguchi C, Matsui H, Nagata S et al. Novel missense mutation in alpha-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 1995; 27(9):2053–2058.
Yamauchi-Takihara K, Nakajima-Taniguchi C, Matsui H et al. Clinical implications of hypertrophic cardiomyopathy associated with mutations in the alpha-tropomyosin gene. Heart 1996; 76(1):63–65.
Jaaskelainen P, Soranta M, Miettinen R et al. The cardiac beta-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol 1998; 32(6):1709–1716.
Coviello DA, Maron BJ, Spirito P et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a “hot spot” in the alpha-tropomyosin gene. J Am Coll Cardiol 1997; 29(3):635–640.
Jongbloed RJ, Marcelis CL, Doevendans PA et al. Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41(6):981–986.
Karibe A, Tobacman LS, Strand J et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling and poor prognosis. Circulation 2001; 103(1):65–71.
Olson TM, Kishimoto NY, Whitby FG et al. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cariomyopathy. J Mol Cell Cardiol 2001; 33(4):723–732.
Kremneva E, Boussouf S, Nikolaeva O et al. Effects of two familial hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175 Asn and Glu 180Gly, on the thermal unfolding of actin-bound tropomyosin. Biophys J 2004; 87(6):3922–3933.
Hernandez OM, Housmans PR, Potter JD. Invited Review: pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation. J Appl Physiol 2001; 90(3):1125–1136.
Michele DE, Albayya FP, Metzger JM. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes. Nat Med 1999; 5(12):1413–1417.
Prabhakar R, Petrashevskaya N, Schwartz A et al. A mouse model of familial hypertrophic cardiomyopathy caused by a alpha-tropomyosin mutation. Mol Cell Biochem 2003; 251(1–2):33–42.
Westfall MV, Borton AR, Albayya FP et al. Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ Res 2002; 91(6):525–531.
Bottinelli R, Coviello DA, Redwood CS et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 1998; 82(1):106–115.
Michele DE, Gomez CA, Hong KE et al. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent and improved by beta-blockade. Circ Res 2002; 9(3):255–262.
Evans CC, Pena JR, Phillips RM et al. Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2000; 279(5): H2414–2423.
Bing W, Redwood CS, Purcell IF et al. Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp 175 Asn and Glu 180Gly, on Ca2+ regulation of thin filament motility. Biochem Biophys Res Commun 1997; 236(3):760–764.
Golitsina N, An Y, Greenfield NJ et al. Effects of two familial hypertrophic cardiomyopathy-causing mutations on alpha-tropomyosin structure and function. Biochemistry 1997; 36(15):4637–4642.
Bing W, Knott A, Redwood C et al. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alpha-tropomyosin (Asp 175Asn and Glu180Gly) on the regulatory properties of human cardiac troponic determined by in vitro motility assay. J Mol Cell Cardiol 2000; 32(8):1489–1498.
Schachat FH, Bronson DD, McDonald OB. Heterogeneity of contractile proteins. A continuum of troponin-tropomyosin expression in mammalian skeletal muscle. J Biol Chem 1985; 260(2):1108–1113.
Chang AN, Potter JD. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev 2005; 10(3):225–235.
Regitz-Zagrosek V, Erdmann J, Wellnhofer E et al. Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. Circulation 2000; 102(17): E112–116.
Brown JH, Kim KH, Jun G et al. Deciphering the design of the tropomyosin molecule. Proc Natl Acad Sci USA 2001; 98(15):8496–8501.
Mirza M, Marston S, Willott R et al. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem 2005; 280(31):28498–28506.
Mirza M, Robinson P, Kremneva E et al. The effect of mutations in alpha-tropomyosin (E40K and E54K) that cause familial dilated cardiomyopathy on the regulatory mechanism of cardiac muscle thin filaments. J Biol Chem 2007; 282(18):13487–13497.
Jagatheesan G, Rajan S, Petrashevskaya N et al. Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis. Am J Physiol Heart Circ Physiol 2007; 293(2):H949–958.
Pena J, Urboniene D, Goldspink P et al. Phospholamban knockout prevents the development of hypertrophy and cardiac dysfunction in a FHC alpha-tropomyosin (Glu180Gly) mouse model. Paper presented at: Keystone Symposia: Molecular Biology of Cardiac Diseases and Regeneration 2005; Steamboat Springs, CO.
Pena JR, Goldspink PH, Prabhakar R et al. Neonatal Gene Transfer of SERCA2a Improves the Response to β-Adrenergic Stimulation in the-Tropomyosin (Glu180Gly) MouseModel of Familial Hypertrophic Cardiomyopathy. Paper presented at: Scientific Conference on Molecular Mechanisms of Growth, Death and Regeneration in the Myocardium: Basic Biology and Insights Into Ischemic Heart Disease and Heart Failure 2003; Snowbird Conference Center, Snowbird, Utah.
Coutu P, Bennett CN, Favre EG et al. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 2004; 94(9):1235–1241.
Fujino K, Sperelakis N, Solaro RJ. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988; 63(5):911–922.
Du CK, Morimoto S, Nishii K et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 2007; 101(2):185–194.
Rajan S, Williams SS, Jagatheesan G et al. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy. Physiol Genomics 2006; 27(3):309–317.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Wieczorek, D.F., Jagatheesan, G., Rajan, S. (2008). The Role of Tropomyosin in Heart Disease. In: Gunning, P. (eds) Tropomyosin. Advances in Experimental Medicine and Biology, vol 644. Springer, New York, NY. https://doi.org/10.1007/978-0-387-85766-4_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-85766-4_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-85765-7
Online ISBN: 978-0-387-85766-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)